Planet Labs Total Cost of Revenue increased by 14.8% to $39.79M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 70.5%, from $23.34M to $39.79M. Over 4 years (FY 2022 to FY 2026), Total Cost of Revenue shows an upward trend with a 13.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.13M | $19.82M | $20.81M | $23.23M | $23.63M | $24.98M | $24.73M | $23.92M | $24.56M | $27.47M | $29.35M | $26.37M | $28.76M | $28.78M | $23.75M | $23.34M | $29.66M | $31.12M | $34.67M | $39.79M |
| QoQ Change | — | +3.6% | +5.0% | +11.6% | +1.7% | +5.7% | -1.0% | -3.3% | +2.7% | +11.9% | +6.8% | -10.1% | +9.0% | +0.1% | -17.5% | -1.7% | +27.1% | +4.9% | +11.4% | +14.8% |
| YoY Change | — | — | — | — | +23.5% | +26.0% | +18.8% | +2.9% | +3.9% | +10.0% | +18.7% | +10.3% | +17.1% | +4.8% | -19.1% | -11.5% | +3.1% | +8.1% | +46.0% | +70.5% |
| Segment | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $15.61M | $15.61M | $15.61M | $15.61M | $17.06M | $16.13M | $19.15M | $20.59M |
| Total | $24.56M | $27.47M | $29.35M | $26.37M | $28.76M | $28.78M | $29.66M | $31.12M |
Reportable Segment was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.